In this project
we demonstrate the cost-benefit value of the current wastewater treatment
and nitrogen removal processes, for the first time by integrating the
hydrological and chemical data and mass-balance calculations with the measured
values of denitrification - the missing nitrogen sink. The most advanced stable
isotope techniques will be used in the measurement allowing us to get accurate
values of how much we can depend on the ecosystem services in the nitrogen
removal in the current systems. Monitoring and modelling results will be used,
for the first time, to evaluate the denitrification in natural system and
enhanced by the wastewater nitrate.
(Director Per Bovbjerg Pedersen, DTU, JyU work group leader Marja Tiirola, Bonus -project EU/Academy of Finland 2017-2019)
CLEANAQ develops
novel procedures for end-of-pipe nutrient removal to improve the
cost-efficiency and to further reduce environmental impact of fish farming in
recirculating aquaculture systems in the Baltic area. Innovative technical
solutions will support one of the main aims of the BONUS program – development
of a food production system with a balanced nutrient budget.
Fish farming
in recirculating aquaculture systems (RAS) provides possibilities for optimized
food production for the benefit of the environment and farming in closed
confinements virtually eliminates the risk of escapees and diseases spreading
to the environment. Within the recirculation loop, nutrients are mainly
converted and subsequently removed from the farming system through particle
separation (e.g. mechanical filters) and water replacement
Alongside
the maturation of RAS technology and an increasing commercialization of this
method of farming, focus is slowly shifting from mechanical/engineering issues
towards more integrated and complex issues such as water quality and
end-of-pipe treatment. The prospective of being able to construct not only a
farming system but actually a complete unit that can handle intake -and
especially discharge water and sludge is gaining more and more attention as
system size and commercialization increases (Dalsgaard et al, 2015). Although
recirculation technology has now reached a fully commercial scale, practical
solutions to the removal or retrieval of the concentrated nutrients in the RAS
discharge are still missing, in particular for brackish and salt water farming.
Cost-efficient solutions are needed for further development of the industry and
CLEANAQ will search for such innovative solutions.
MUTTE -
Mutation screening using ultrasensitive transistor technology
(Project PI Marja Tiirola, Tekes – the Finnish Funding Agency for Innovation 2017-2018)
Even if the throughput of the modern
next-generation sequencing (NGS) devices is tremendous, there is still no ultrasensitive diagnosis technology available in the
market, which limits the detection
of circulating tumor cells or tumor DNA from liquid biopsies. New technology
can enable a novel way to utilize the widely spread NGS device for detection of
mutations. Ultimate sensitivity is gained through amplification of the target
signal using an exponential chemical reaction and tracking the signal using
commonly available semiconductor sequencing device. This is one implication of
the on-going ERC consolidator grant project “Micro-RIP”, which has enabled determination
of radiation from single molecules using semiconductor transistor array. When
adopted into chemiluminescense detection in the MUTTE project, the technology aims
to decrease the cost of cancer therapy and lead to higher treatment success.
This can build an enormous value in terms of money and human wellbeing. The cost of cancer in the European Union is
estimated €126 billion in 2009, with healthcare accounting for €51 billion
(40%). The worldwide cancer diagnostic markets have been predicted to increase
to $13 billion by 2020. TEKES funding is used for setting up the protocol in the chemiluminescense mode, testing the
sensitivity and needed software in screening colorectal cancer KRAS mutations,
evaluation of the best commercialization
options and defining the business models for the scientific and hospital scale
solutions